Labs to monitor during GLP-1 therapy: what changes and why
Six labs worth tracking, the rough cadence, and the changes you would expect to see.
TL;DR
- A six-test panel — A1c, fasting insulin, lipid panel with ApoB, comprehensive metabolic panel, lipase, B12 — covers most of what changes on GLP-1.
- Baseline, three months, then every six months is the cadence used in most published protocols.
- The labs tell you whether the drug is doing the metabolic work the trials suggest, and whether anything needs attention.
What it is
A GLP-1 monitoring panel is the set of blood tests a clinician orders before and during GLP-1 therapy. The goal is twofold: confirm the metabolic improvement and catch any side-effect signal early. The panel is not exotic — most of the tests are already on a standard preventive-care panel. The cadence and what to look for are what change.
How it works
Think of the panel like the dashboard of a car you have just had serviced. You want to see fuel efficiency improve (A1c, fasting insulin), engine load shift (lipids, ApoB), the cooling and electrical systems stay fine (kidney function, B12), and no warning lights blinking (lipase). On GLP-1 therapy, A1c usually drops, fasting insulin usually falls, ApoB tends to improve, and kidney function generally improves or holds — with the SELECT and FLOW trials reinforcing the kidney findings in specific populations (Perkovic et al., NEJM, 2024).
Who asks about it
People come to this question after starting a GLP-1 or considering one and wanting to know what “monitoring” actually means in practice. The honest version: it is six tests, two or three times a year, that tell most of the story.
What the research says
A1c is the most validated GLP-1 monitoring marker — it consistently falls in trials of semaglutide and tirzepatide in people with diabetes. Fasting insulin and HOMA-IR typically improve. ApoB and triglycerides usually improve. Lipase elevation can occur and may be transient; clinicians weigh it against symptoms. B12 deficiency is more commonly cited with metformin than with GLP-1, but is reasonable to screen in patients with low intake or absorption concerns. The FDA’s postmarket safety information lists pancreatitis, gallbladder disease, and acute kidney injury (in the context of severe dehydration) as monitorable risks (FDA, 2024).
What to know before considering it
GLP-1 therapy requires a licensed clinician evaluation, both at baseline and during dose changes. Compounded GLP-1 is prepared by state-licensed 503A pharmacies from an FDA-approved active pharmaceutical ingredient; the compounded version is not FDA-approved. Symptoms like severe abdominal pain, persistent vomiting, or new urinary changes are reasons to call your clinician, not to wait for the next routine lab.
The Halftime POV
The dashboard frame matters. Six labs at a sensible cadence tells most of the story, and removes the mystery from “what is this drug actually doing to my body.” Clinical monitoring is not a barrier to access — it is the access.
Related reading:
- A1c and fasting glucose explained
- Fasting insulin: the marker your panel misses
- ApoB vs LDL: which cardiovascular marker matters
FAQ
Q: What labs should I get on a GLP-1? A: A reasonable monitoring panel includes A1c, fasting insulin, lipid panel with ApoB, comprehensive metabolic panel for kidney function, lipase, and B12. Frequency is usually baseline, three months, and then every six months.
Q: Does GLP-1 affect kidney function? A: GLP-1 therapy has shown kidney-protective effects in trials like FLOW. Acute kidney injury from dehydration during severe nausea or vomiting is a known but uncommon adverse event, which is why a comprehensive metabolic panel is worth monitoring.
Q: Should I check lipase on GLP-1? A: Lipase is sometimes checked because pancreatitis is a labeled GLP-1 risk. Routine lipase screening in asymptomatic patients is debated; symptomatic patients warrant immediate evaluation.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026). Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
